| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
65,460 |
61,895 |
$3.79M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
20,347 |
17,587 |
$1.72M |
| J1602 |
Injection, golimumab, 1 mg, for intravenous use |
582 |
498 |
$865K |
| 99205 |
Prolong outpt/office vis |
6,590 |
6,385 |
$779K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
7,211 |
7,024 |
$647K |
| J0490 |
Injection, belimumab, 10 mg |
281 |
245 |
$628K |
| 99215 |
Prolong outpt/office vis |
7,253 |
6,845 |
$618K |
| Q5121 |
Injection, infliximab-axxq, biosimilar, (avsola), 10 mg |
330 |
289 |
$531K |
| J3262 |
Injection, tocilizumab, 1 mg |
434 |
309 |
$490K |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
191 |
160 |
$234K |
| 99443 |
|
3,068 |
2,928 |
$194K |
| J0129 |
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) |
57 |
50 |
$121K |
| 96415 |
|
4,027 |
3,357 |
$112K |
| 99442 |
|
2,744 |
2,578 |
$102K |
| 36415 |
Collection of venous blood by venipuncture |
31,642 |
29,752 |
$80K |
| J0897 |
Injection, denosumab, 1 mg |
180 |
173 |
$78K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,534 |
1,202 |
$47K |
| Q5104 |
Injection, infliximab-abda, biosimilar, (renflexis), 10 mg |
48 |
41 |
$41K |
| Q5103 |
Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg |
12 |
12 |
$22K |
| 76881 |
|
541 |
351 |
$17K |
| 20611 |
|
186 |
140 |
$12K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
1,354 |
1,230 |
$6K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
400 |
325 |
$5K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
630 |
594 |
$4K |
| 20610 |
|
53 |
45 |
$3K |
| 81002 |
|
701 |
684 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
26 |
24 |
$1K |
| 99441 |
|
120 |
117 |
$1K |
| 20600 |
|
50 |
26 |
$677.98 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
65 |
64 |
$376.87 |
| J1020 |
Injection, methylprednisolone acetate, 20 mg |
161 |
140 |
$306.46 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
39 |
36 |
$195.13 |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
54 |
42 |
$114.65 |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
16 |
13 |
$105.70 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
26 |
26 |
$41.81 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
33 |
24 |
$20.83 |
| 80053 |
Comprehensive metabolic panel |
14 |
13 |
$0.00 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
13 |
13 |
$0.00 |
| 85652 |
|
13 |
13 |
$0.00 |
| 86140 |
|
15 |
14 |
$0.00 |